2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1307

Anatomical Patterns Suggest the Involvement of Biomechanical Stress in the Pathogenesis of Erosions in Rheumatoid Arthritis
Abstract Number: 1950

ANCA-Associated Vasculitides and IgG4-Related Disease: An Overlapping Syndrome? a European Observational Study of 18 Patients
Abstract Number: 918

Anergic B Cells May Preserve Peripheral Tolerance in Lupus-Prone Congenic Mice
Abstract Number: 468

Angiotensin II Exacerbates Bone Destruction in TNF-Transgenic Arthritis Mice
Abstract Number: 2113

Anti-Carbamylated Protein Antibody (cross)-Reactivity Against Multiple Carbamylated Protein Antigens
Abstract Number: 2608

Anti-CCP Antibody Titers Decrease with Altered B-Cell Subpopulation in RA Patients Treated with Tocilizumab
Abstract Number: 130

Anti-CCP Status Determines the Power Doppler Oscillation Pattern in Rheumatoid Arthritis – a Prospective Study
Abstract Number: 503

Anti-CCP Titer and Prevalence Is Influenced By Age at Rheumatoid Arthritis Onset- Analysis Based on a Nationwide Database in Japan
Abstract Number: 574

Anti-CCP3.1 and Anti-CCP3-IgA Antibodies Are Associated with Increasing Age in Subjects without Rheumatoid Arthritis
Abstract Number: 576

Anti-CCP3.1 and Anti-CCP3-IgA Are Elevated in RA-Free Subjects with Idiopathic Pulmonary Fibrosis
Abstract Number: 491

Anti-Citrullinated Peptide Antibodies Testing Rate over Time in Newly Diagnosed RA Patients – Data from Three Administrative Claims Databases (2007–2014)
Abstract Number: 1116

Anti-Citrullinated Protein Antibodies Promote Synovial Fibroblasts Migration and Adhesion through a Peptidylarginine Deiminases (PAD) Dependent Pathway
Abstract Number: 2624

Anti-Citrullinated Protein Antibodies Titers Are Independently Modulated By Disease Activity and Synthetic or Biologic Dmards in a Seropositive Early Arthritis Population
Abstract Number: 1499

Anti-Cyclic Citrullinated Peptide Antibodies and Severity of Interstitial Lung Disease with Rheumatoid Arthritis
Abstract Number: 512

Anti-Cyclic Citrullinated Protein Antibody (ACPA) Positivity in General Population and Follow-up Results for ACPA Positive Persons

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].